{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/luts-in-men/management/urinary-retention/","result":{"pageContext":{"chapter":{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention","depth":2,"htmlHeader":"<!-- begin field 49848827-4fa7-4713-b680-b94b0ca4027d --><h2>Scenario: Urinary retention (acute, acute on chronic, chronic)</h2><!-- end field 49848827-4fa7-4713-b680-b94b0ca4027d -->","summary":"Covers the management of men with acute, chronic, and acute-on-chronic urinary retention.","htmlStringContent":"<!-- begin item 812eb2ec-bfb0-4915-a389-91812dd5c37b --><!-- begin field 7b2da115-7fa5-4a6b-9893-acbc0157d407 --><p>From age 40 years onwards (Male).</p><!-- end field 7b2da115-7fa5-4a6b-9893-acbc0157d407 --><!-- end item 812eb2ec-bfb0-4915-a389-91812dd5c37b -->","topic":{"id":"fdcce69d-578e-5994-a7c2-84be40932dd8","topicId":"a7bf3f2d-1d9e-47c0-9dd3-26731c4d092b","topicName":"LUTS in men","slug":"luts-in-men","lastRevised":"Last revised in March 2019","chapters":[{"id":"149361eb-636f-59a5-a2e2-b067d629a065","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c7972342-637c-56a9-8783-c1e8314e7fd1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7105be47-f38b-5335-b14d-69db43326579","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c8165ab8-59af-557d-824d-58f09041698f","slug":"changes","fullItemName":"Changes"},{"id":"776566d2-009e-5ebd-ac21-e5605029213a","slug":"update","fullItemName":"Update"}]},{"id":"4c1332b1-3f4f-530f-bb70-d627804caa79","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d434ba09-30c6-5bfc-bb6f-87e952a1b33a","slug":"goals","fullItemName":"Goals"},{"id":"702b01d3-71e8-5daf-a985-3935596391f5","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0aef110d-14b4-5ae2-9da0-a07cc4aef9ef","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7fcf6ae7-162e-5b90-84fb-2a79f82d420e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1c91c138-4e44-571e-8ac0-8e62f8dca310","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4fe99a13-4e80-5c28-b091-216c8a8d7f82","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"3a98397f-2bc4-5e01-90d6-03d6fbe400c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d41a85e2-c1cb-5198-afc7-7c4fbe28ae24","slug":"definitions","fullItemName":"Definitions"},{"id":"fd0f4942-31d6-517a-a10b-d341e34a2504","slug":"causes-of-luts","fullItemName":"Causes of LUTS"},{"id":"3af3e2a4-26b3-5a77-9e8b-3d393388e624","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1c6eecc6-b753-5918-adae-dc2d864d88fa","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"d1432aa0-7841-5eec-85c4-e344d4629bd9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"762c13bd-ead4-5aa6-b460-701b0572f9aa","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8874a841-31e1-5356-a3f6-7bff9c28c693","slug":"assessment","fullItemName":"Assessment"},{"id":"8c77fb91-6134-565b-b1ef-4452e83c424f","slug":"investigations","fullItemName":"Investigations"}]},{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d790431-a0c8-5ca1-8143-be639ea2ec02","slug":"voiding-symptoms","fullItemName":"Scenario: Voiding symptoms"},{"id":"b1451e1b-3776-5aa0-94b0-79be5fb01831","slug":"overactive-bladder","fullItemName":"Scenario: Overactive bladder"},{"id":"f4818005-dc3a-52b2-ac5d-d14f0d6ac0db","slug":"nocturnal-polyuria","fullItemName":"Scenario: Nocturnal polyuria"},{"id":"fb3acb54-4d76-5aad-ab1c-7b0b3d9443a3","slug":"stress-urinary-incontinence","fullItemName":"Scenario: Stress urinary incontinence"},{"id":"c511bb10-1198-548d-8e23-a1f6e98df926","slug":"urinary-retention","fullItemName":"Scenario: Urinary retention"},{"id":"0a3e83b8-a00f-520f-b21f-9ef6cc6440e7","slug":"post-micturition-dribble","fullItemName":"Scenario: Post-micturition dribble"}]},{"id":"40ed844e-b196-5a8a-9d88-2ff299e04d85","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c9f3458-4ae7-5003-a4f9-ed026a61a3d0","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"2f32bd76-64d1-51c9-bc96-4173829de1b5","slug":"5-alpha-reductase-inhibitors","fullItemName":"5-alpha reductase inhibitors"},{"id":"d7f3eec1-9124-5d3a-a793-15707f8cfeda","slug":"antimuscarinics","fullItemName":"Antimuscarinics"},{"id":"507e078b-b3d0-527c-b71d-0b1101948c01","slug":"mirabegron","fullItemName":"Mirabegron"},{"id":"7c2851da-6e40-5415-ada7-7466766510fa","slug":"furosemide","fullItemName":"Furosemide"},{"id":"ae12d520-87b4-5400-8cfa-79a25bb39663","slug":"desmopressin","fullItemName":"Desmopressin"}]},{"id":"dca797b5-427f-5ed5-94e4-3ad565f628a9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5e289c42-8089-5739-9683-20c374967578","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"07accac1-c375-54a3-92cc-d2cd8a2bb914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c05a5332-4c79-595e-b066-09dcd9841073","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e5cf2cc-d3d4-5d7d-82a7-3dd1ae3c65d9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47ea76bd-52d3-5c5a-8d1f-f574eec081bd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"38a45d79-a74f-5ca9-a844-f16ea2c0ab75","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0b3152db-f873-5814-b35f-54711f247dff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"60ffa7b7-da40-599a-bffa-e6e68db76a97","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"bae48f35-562d-5896-8b40-6ef67df0208a","slug":"acute-urinary-retention","fullItemName":"Acute urinary retention","depth":3,"htmlHeader":"<!-- begin field 3b093ab4-9470-46bd-9a8e-baadd7a1e505 --><h3>How should I manage acute urinary retention in a man?</h3><!-- end field 3b093ab4-9470-46bd-9a8e-baadd7a1e505 -->","summary":null,"htmlStringContent":"<!-- begin item dc0740e8-3363-4907-9ade-bb09c2b3e706 --><!-- begin field 75826923-ebb3-452f-8b4b-c1d3c3b26e15 --><ul><li><strong>If this is the first episode of acute urinary retention, </strong>arrange hospital admission.<ul><li>If the expertise and facilities are available, catheterize before admission.</li><li>Otherwise, admit the man urgently for catheterization and investigation of the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/background-information/causes-of-luts/#acute-urinary-retention\">cause</a>.</li></ul></li><li><strong>If the man has recurrent acute retention or acute-on-chronic urinary retention, </strong>admit the man, or insert a urethral catheter. Discuss and decide on treatment to prevent or manage recurrent urine retention. Options include:<ul><li><strong>An alpha-blocker (modified-release alfuzosin 10 mg a day) </strong>— in men over 65 years of age.<ul><li>Start at least 24 hours before attempting to remove the catheter.</li><li>After removing the catheter, confirm over several hours that the man can void freely.</li><li>The licensed duration of use is for 2–3 days during catheterization, and for 1 day after removal (maximum 4 days). However, some experts recommend that the alpha-blocker should be continued until the man has been fully investigated to determine the <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/background-information/causes-of-luts/#acute-urinary-retention\">cause</a> and to assess renal function.</li><li>For detailed prescribing information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/luts-in-men/prescribing-information/alpha-blockers/\">Alpha-blockers</a>.</li></ul></li><li><strong>Intermittent urethral catheterization </strong>— refer the man or his carer to a continence nurse for training in catheterization.</li><li><strong>A long-term indwelling catheter </strong>— only if intermittent catheterization is not appropriate or practical.</li></ul></li></ul><!-- end field 75826923-ebb3-452f-8b4b-c1d3c3b26e15 --><!-- end item dc0740e8-3363-4907-9ade-bb09c2b3e706 -->","subChapters":[{"id":"a30caac3-db74-5697-8e5a-da1b877561ae","slug":"basis-for-recommendation-6ad","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 11f8f595-811b-4517-9d8e-84674541191c --><h4>Basis for recommendation</h4><!-- end field 11f8f595-811b-4517-9d8e-84674541191c -->","summary":null,"htmlStringContent":"<!-- begin item 6ad82d71-b79d-4486-a7df-bda40fb6c6d5 --><!-- begin field fa43d9d3-be6c-42d2-a8bf-ef5bc6d3de38 --><p>These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guidelines <em>The management of lower urinary tract symptoms in men </em>(full NICE guideline) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">National Clinical Guideline Centre, 2015</a>] and <em>Lower urinary tract symptoms in men: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2015</a>].</p><ul><li>Modified-release alfuzosin is licensed for the treatment of acute urinary retention associated with benign prostatic hyperplasia in men over 65 years of age. In this indication, no benefit has been established in people younger than 65 years of age or if treatment is extended beyond 4 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">ABPI, 2017a</a>].</li></ul><!-- end field fa43d9d3-be6c-42d2-a8bf-ef5bc6d3de38 --><!-- end item 6ad82d71-b79d-4486-a7df-bda40fb6c6d5 -->","subChapters":[]}]},{"id":"36164d3d-ae8d-5d6f-ac05-925a590f4e8e","slug":"chronic-urinary-retention","fullItemName":"Chronic urinary retention","depth":3,"htmlHeader":"<!-- begin field d8d676f2-a076-49f2-b097-ce3203daa259 --><h3>How should I manage chronic urinary retention in a man?</h3><!-- end field d8d676f2-a076-49f2-b097-ce3203daa259 -->","summary":null,"htmlStringContent":"<!-- begin item 1d85a0a4-6c3c-42a9-a2c6-bfa0fd5961cd --><!-- begin field 4213294d-f591-452c-87ef-2c6b5c6ca9e3 --><ul><li><strong>Exclude non-obstructive causes of reduced urine flow </strong>(such as chronic heart failure).</li><li><strong>Check serum creatinine </strong>to assess renal function.</li><li><strong>Refer the man for specialist assessment.</strong><ul><li>Consider seeking specialist advice about arranging imaging of the upper urinary tract and kidneys while the man is waiting to be seen.</li></ul></li><li><strong>Advise the man about management options in secondary care, including:</strong><ul><li>No catheterization, but follow up with regular monitoring of renal function, volume of urinary retention, and any changes in imaging of upper renal tract.</li><li>Intermittent urethral catheterization (performed by the man or his carer).</li><li>A permanent indwelling catheter.</li><li>Surgery to divert the urine externally (urostomy).</li></ul></li></ul><!-- end field 4213294d-f591-452c-87ef-2c6b5c6ca9e3 --><!-- end item 1d85a0a4-6c3c-42a9-a2c6-bfa0fd5961cd -->","subChapters":[{"id":"0b7dfe93-a5d9-5eb1-b535-c679849ab7f2","slug":"basis-for-recommendation-007","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d73d6a08-7602-4490-986f-fb8b7b89f077 --><h4>Basis for recommendation</h4><!-- end field d73d6a08-7602-4490-986f-fb8b7b89f077 -->","summary":null,"htmlStringContent":"<!-- begin item 0078564f-058f-4240-9441-95bb167262ed --><!-- begin field daaf599c-6177-43d4-b1d3-4cc3ea835873 --><p>These recommendations are based on the National Institute for Health and Clinical Excellence (NICE) guidelines <em>The management of lower urinary tract symptoms in men </em>(full NICE guideline) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">National Clinical Guideline Centre, 2015</a>] and <em>Lower urinary tract symptoms in men: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/luts-in-men/references/\">NICE, 2015</a>].</p><h5>Assessing renal function with serum creatinine</h5><ul><li>NICE based this recommendation on the expert opinion of the guideline development group (GDG) because no relevant studies were found that assessed how measuring renal function affects clinical outcomes in men with lower urinary tract symptoms (LUTS).</li><li>The NICE GDG considered serum creatinine to be the most reliable routine test for renal function. They highlighted that many laboratories report estimated glomerular filtration rate (eGFR) whenever serum creatinine is measured and that (when required) renal function can be more accurately assessed by measuring creatinine clearance.</li></ul><h5>Referral for specialist assessment</h5><ul><li>NICE based this recommendation on the expert opinion of the GDG because no directly relevant clinical trials were identified.</li></ul><h5>Seeking specialist advice about radiological imaging</h5><ul><li>NICE found no studies that assessed how radiological imaging affects clinical outcomes in men with LUTS. This recommendation is therefore based on the expert opinion of the GDG.</li></ul><!-- end field daaf599c-6177-43d4-b1d3-4cc3ea835873 --><!-- end item 0078564f-058f-4240-9441-95bb167262ed -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}